Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neurologix initiates Phase II Parkinson’s disease trial
The purpose of the trial is to validate the safety and efficacy of Neurologix’s gene transfer therapy, a novel non-dopaminergic approach to restore motor function in Parkinson’s patients
The purpose of the trial is to validate the safety and efficacy of Neurologix’s gene transfer therapy, a novel non-dopaminergic approach to restore motor function in Parkinson’s patients
CD-NP is a novel chimeric natriuretic peptide in clinical development for the treatment of acute heart failure. CD-NP was designed to preserve the favorable effects of current therapies
Tasigna is approved in Japan for the treatment of certain forms of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia, a rare and potentially fatal cancer of the white blood
According to the company, the Obagi Rosaclear System is the first and only complete prescription-based system developed specifically for treating the signs and symptoms of rosacea. The all-in-one
The small proof-of-concept diabetic vitrectomy (DV) trial has been enrolling slowly due to newer surgical procedures that have resulted in a decreasing number of vitrectomy procedures in the
The special protocol assessment (SPA) provides an agreement between the FDA and Seattle Genetics regarding the design, including size and clinical endpoints, of the pivotal trial to support
Under the terms of the agreement, Sysmex and Epigenomics will assess the suitability of Sysmex’s molecular diagnostics instrumentation for the detection of DNA methylation cancer biomarkers in blood.
The trials, known as the Gemini program, will study vedolizumab for the treatment of ulcerative colitis and Crohn’s disease, the two main types of inflammatory bowel disease (IBD).
The application, filed by Scolr on August 5, 2008, seeks approval to market a 120mg 12 hour pseudoephedrine tablet based on its patented Controlled Delivery Technology (CDT) platform.
Under the terms of the agreement S*BIO is eligible to receive up to $112.5 million in payments. This includes an upfront fee, development and sales milestone payments and